Addex Therapeutics Ltd (ADXN) is not a strong buy at this time for a beginner investor with a long-term strategy. The lack of positive trading signals, bearish technical indicators, declining financial performance, and absence of significant catalysts suggest that the stock does not present a compelling investment opportunity currently.
ADXN exhibits bearish technical indicators. The MACD histogram is negative and contracting, RSI is neutral at 45.803, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot level of 6.355, with key support at 5.751 and resistance at 6.958. There is no clear upward momentum.
NULL identified. No recent news or significant trading trends from hedge funds or insiders.
also declined by -1.79%. Additionally, financial performance shows a YoY revenue decline of -7.97%.
In Q3 2025, revenue dropped by -7.97% YoY to 62,014.92. Net income improved slightly but remains negative at -1,972,013.2 (+11.60% YoY). EPS and gross margin showed no change YoY, remaining at -0.02 and 100, respectively. Overall, the financials indicate weak growth trends.
No recent analyst ratings or price target changes are available for ADXN.
